Scheinfeld Noah
Department of Dermatology, St Lukes Roosevelt Hospital, New York, USA.
J Dermatolog Treat. 2005;16(4):207-12. doi: 10.1080/09546630510011810.
Tigecycline derived from minocycline. It is part of a new class of antibiotics called glycylcyclines. Tigecycline is given intravenously and has activity against a variety of gram-positive and gram-negative bacterial pathogens, many of which are resistant to existing antibiotics. Tigecycline successfully completed phase III trials in which it was at least equal to intravenous vancomycin and aztreonam to treat complicated skin and skin structure infections (cSSSI), and to intravenous imipenem and cilastatin to treat complicated intra-abdominal infections (cIAI). Tigecycline side effects are primarily digestive upset. It should be a valuable addition to the armamentarium to treat even the most resistant pathogens.
替加环素由米诺环素衍生而来。它属于一类名为甘氨酰环素的新型抗生素。替加环素通过静脉给药，对多种革兰氏阳性和革兰氏阴性细菌病原体具有活性，其中许多病原体对现有抗生素耐药。替加环素成功完成了III期试验，在治疗复杂性皮肤和皮肤结构感染（cSSSI）方面，其疗效至少与静脉注射万古霉素和氨曲南相当；在治疗复杂性腹腔内感染（cIAI）方面，其疗效至少与静脉注射亚胺培南和西司他丁相当。替加环素的副作用主要是胃肠道不适。它将成为治疗甚至是最耐药病原体的药物库中的一项宝贵补充。
